Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β

Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β

IntroductionLomerizine is a calcium channel blocker that crosses the blood–brain barrier and is used clinically in the treatment of migraines. However, whether lomerizine is beneficial in modulating neuroinflammatory responses has not been tested yet.MethodsTo assess the potential of lomerizine for...

Full description

Bibliographic Details
Main Authors: Jin-Hee Park, Jeong-Woo Hwang, Hyun-ju Lee, Geum Mi Jang, Yoo Joo Jeong, Joonho Cho, Jinsoo Seo, Hyang-Sook Hoe
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
lomerizine
neuroinflammation
tauopathy
Alzheimer’s disease
DYRK1A
NLRP3
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1150940/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1150940/full

Similar Items